Highroad

Highroad invests from seed stage through growth equity, covering the full lifecycle of early-stage technology companies. The firm's strategy spans pre-revenue startups to later-stage businesses scaling internationally, with a primary emphasis on Israeli-founded enterprise software companies. Stage-specific check sizes are not publicly disclosed.

Highroad concentrates on enterprise technology sectors where Israeli engineering talent historically excels. Core sectors include enterprise software, AI and machine learning applications, cybersecurity platforms, and financial technology infrastructure. The firm does not publicly disclose explicit sector exclusions or negative screening criteria.

Highroad maintains a concentrated portfolio strategy, directing capital into Israeli-founded startups building for global enterprise markets. The firm participates in direct equity investments, typically alongside international venture capital firms that co-invest in Israeli-origin innovation. Highroad's sourcing network draws from Israel's elite military technology units and university research pipelines.

Highroad operates as a private equity firm, but its investment activities—spanning seed, early-stage, and growth investing—align more closely with a venture capital model. The firm's legal structure, fund vehicles, and limited partner base are not publicly disclosed. Highroad maintains a lean operational footprint consistent with a boutique venture manager.

Highroad's disclosed strategy focuses on direct equity investments in technology companies, but the firm has not publicly clarified whether it also allocates capital to external funds. Many Israeli investment managers blend direct deals with limited partner commitments to global venture funds—whether Highroad employs a hybrid model remains unclear from available public records.

Highroad has not publicly named its investment committee members or disclosed its decision-making governance structure. The firm's leadership team, investment professionals, and operational partners are not listed on publicly available sources. This opacity is not unusual for boutique Israeli investment firms, but it limits external allocator diligence.

Highroad's typical deal structure involves co-investing alongside global venture capital firms in Israeli-founded companies. The firm has not published a formal co-investment policy or disclosed its typical co-investment partners. Allocators interested in co-investment access should engage the firm directly, as no standard arrangement is publicly documented.